News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arrowhead Research Corporation (ARWR) Subsidiary Unidym, Inc. Licenses Technology to Incorporate Carbon Nanotubes into Miniaturized Medical Devices for the Treatment of Cardiovascular Disease



8/3/2007 6:10:10 AM

PASADENA, Calif. & CHARLESTON, W.Va.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ:ARWR) and Paragon Intellectual Properties, LCC announced today that Arrowhead’s majority-owned subsidiary, Unidym Inc., has signed an exclusive license agreement with Paragon’s majority-owned subsidiary, Nanotech Catheter Solutions, LLC (NCS). NCS will use Unidym’s carbon nanotube technology in the development of medical devices for the treatment of cardiovascular disease. Under the terms of the agreement, Unidym will receive a 20 percent equity stake in NCS, and the parties will negotiate a supply agreement or royalty.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES